Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Faropenem→

Faropenem Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
106560-14-9
PubChem CID
65894
Molecular formula
C12H15NO5S
Molecular weight
285.32 g/mol
Drug class
Oral penem-class beta-lactam antibacterial antibiotic
Mechanism of action
Inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins and blocking peptidoglycan cross-linking, resulting in bactericidal activity against susceptible organisms.

Sources: PubMed literature search — Faropenem antibacterial pharmacology · PubChem — Faropenem · FDA product information

Identification source: PubChem record (CID 65894). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Faropenem Environmental Risk Assessment (ERA) (the Faropenem ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.